The Tear Film and Ocular Surface Society’s Meibomian Gland Workshop was tasked to sort through the literature to determine proper terminology of conditions affecting the lid margin. Review the terminology, gland anatomy, gland expression classifications, and treatment strategies.
A new compact, portable device for rapid, high-definition meibomian gland imaging (LipiScan, TearScience) is an efficient screening tool for patients with complaints of dry eye and/or candidates for surgical procedures in which pre-existing dry eye could affect outcomes.
Shire plc obtained U.S. Food and Drug Administration (FDA) approval for Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
Ophthalmologists have been waiting more than a decade for a new treatment option for their dry eye patients—and the anticipation is finally over. Lifitegrast ophthalmic solution 5% (Xiidra, Shire Ophthalmics) is a twice-daily eye drop solution and is the only FDA-approved drug indicated to treat the signs and symptoms of dry eye disease, according to the company.
Ron Melton, OD, FAAO, and Randall Thomas, OD, MPH, FAAO, discussed common practices for treating dry eye, meibomian gland dysfunction (MGD), and blepharitis at the American Optometric Association (AOA) annual meeting. Here are a few medical management pearls from their discussion.
Certainly, one would assume that nothing could be safer than a product designed for use with children. Television commercials with smiling, happy babies covered in frothy bubbles imply the product is harmless. Ubiquitous marketing alone creates a subconscious sense of safety for both doctor and patient.